Scarica l'app Stockscreener
18.00
2.60%
-0.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$18.48
Aprire:
$18.33
Volume 24 ore:
7.22M
Relative Volume:
0.80
Capitalizzazione di mercato:
$20.67B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-69.50
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
-1.42%
1M Prestazione:
+0.95%
6M Prestazione:
+23.37%
1 anno Prestazione:
+73.91%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$17.86
$18.70
Portata 52W:
$9.92
$18.75
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
18.00 | 20.67B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
20.24 | 64.66B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.41 | 45.96B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.27 | 45.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
81.03 | 33.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
587.50 | 25.20B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-23 | Iniziato | Oppenheimer | Outperform |
| 2026-09-09 | Iniziato | Leerink Partners | Outperform |
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.
What US Small Cap Value Portfolio ETF (DFSV) Bought: Dick's Leads on Wednesday - Yahoo Finance
Form 4 Viatris Inc: David S. Simmons (Director) For: 30 September - Investing.com UK
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada
Pacira BioSciences jumps 44% after Viatris agre... - Pluang
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
A $36.50-a-share cash deal would add a wholly owned subsidiary to Viatris (VTRS). - Stock Titan
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com South Africa
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc. - Ashurst Perkins Coie
Doubling up in pain: Viatris pays $1.65B, Pacira gets relief - BioWorld News
VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research
Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research
Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com Nigeria
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com South Africa
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com UK
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research
More than 300,000 people took part in Forbes' employer survey; Viatris made the list. - Stock Titan
Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street
Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView
Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viatris Inc Azioni (VTRS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Paul Campbell | Officer |
Jun 25 '26 |
Proposed Sale |
16.17 |
50,076 |
809,678 |
0 |
| Campbell Paul | See Remarks |
Jun 25 '26 |
Sale |
16.17 |
50,076 |
809,784 |
316,212 |
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '26 |
Option Exercise |
0.00 |
42,988 |
0 |
122,558 |
| Campbell Paul | See Remarks |
Mar 23 '26 |
Sale |
13.28 |
21,350 |
283,539 |
366,288 |
| Paul Campbell | Officer |
Mar 23 '26 |
Proposed Sale |
13.28 |
21,350 |
283,508 |
0 |
| MARK RICHARD A | Director |
Mar 06 '26 |
Option Exercise |
0.00 |
24,835 |
0 |
116,145 |
| Campbell Paul | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
28,974 |
0 |
398,956 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 06 '26 |
Option Exercise |
0.00 |
130,701 |
0 |
1,374,576 |
| HIGGINS MELINA E | Director |
Mar 06 '26 |
Option Exercise |
0.00 |
24,835 |
0 |
146,048 |
| Groothuis Leo Frans | Director |
Mar 06 '26 |
Option Exercise |
0.00 |
24,835 |
0 |
63,567 |
0.46%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):